99mTc-DTPA-surfactant inhalation in adult respiratory distress syndrome (ARDS): a new diagnostic-therapeutic tool.
ARDS is a life-threatening pulmonary disease with a rapidly progressive decline due mainly to multi-organ failure.  Death occurs in 50-75% of ARDS cases.  The diagnosis and therapy should start in the first six days of this fatal disease when mortality is at its lowest level.  The 99mTc-DTPA-measured pulmonary alveolar epithelial permeability (PAEP) is strikingly increased in ARDS even in comparison to heavy smokers.  Furthermore, surfactant inhalation has been shown to be of therapeutic value.  In five ARDS patients with increased PAEP (T0.5 = 12% pred.) 20 mg/kg of aerosolized surfactant determined a dramatic improvement in blood gases and PAEP (51.8% pred.)  No patient remained dependent on ventilatory treatment.
Todisco
T
T
University of Perugia, Perugia, Italy.
Cosmi
E
E
Dottorini
M
M
Baglioni
S
S
Eslami
A
A
Fedeli
L
L
Palumbo
R
R
D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010539:Permeability; D011650:Pulmonary Alveoli / Q000503:physiopathology; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012128:Respiratory Distress Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D016284:Technetium Tc 99m Pentetate / Q000008:administration & dosage*